147 related articles for article (PubMed ID: 11224758)
1. Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease.
Bokor D; Chambers JB; Rees PJ; Mant TG; Luzzani F; Spinazzi A
Invest Radiol; 2001 Feb; 36(2):104-9. PubMed ID: 11224758
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging.
Morel DR; Schwieger I; Hohn L; Terrettaz J; Llull JB; Cornioley YA; Schneider M
Invest Radiol; 2000 Jan; 35(1):80-5. PubMed ID: 10639039
[TBL] [Abstract][Full Text] [Related]
3. SonoVue in transcranial Doppler investigations of the cerebral arteries.
Kaps M; Legemate DA; Ries F; Ackerstaff RG; Markus H; Pezzoll C; Llull JB; Spinazzi A
J Neuroimaging; 2001 Jul; 11(3):261-7. PubMed ID: 11462292
[TBL] [Abstract][Full Text] [Related]
4. [The effect of SonoVue in endocardial border delineation and myocardial perfusion].
Fang LG;
Zhonghua Nei Ke Za Zhi; 2004 Nov; 43(11):824-7. PubMed ID: 15634541
[TBL] [Abstract][Full Text] [Related]
5. Safety of Sulfur Hexafluoride Microbubbles in Sonography of Abdominal and Superficial Organs: Retrospective Analysis of 30,222 Cases.
Tang C; Fang K; Guo Y; Li R; Fan X; Chen P; Chen Z; Liu Q; Zou Y
J Ultrasound Med; 2017 Mar; 36(3):531-538. PubMed ID: 28072475
[TBL] [Abstract][Full Text] [Related]
6. Safety and ultrasound-enhancing potentials of a new sulfur hexafluoride-containing agent in the cerebral circulation.
Kaps M; Seidel G; Bokor D; Modrau B; Algermissen C
J Neuroimaging; 1999 Jul; 9(3):150-4. PubMed ID: 10436756
[TBL] [Abstract][Full Text] [Related]
7. The safety of Sonovue in abdominal applications: retrospective analysis of 23188 investigations.
Piscaglia F; Bolondi L;
Ultrasound Med Biol; 2006 Sep; 32(9):1369-75. PubMed ID: 16965977
[TBL] [Abstract][Full Text] [Related]
8. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
9. Safety and Tolerability of SonoVue® in Patients with Large Artery Anterior Circulation Acute Stroke.
Baracchini C; Viaro F; Favaretto S; Palmieri A; Kulyk C; Causin F; Farina F; Ballotta E
J Neuroimaging; 2017 Jul; 27(4):409-413. PubMed ID: 28000971
[TBL] [Abstract][Full Text] [Related]
10. Adverse reactions after the use of sulphur hexafluoride (SonoVue) echo contrast agent.
Geleijnse ML; Nemes A; Vletter WB; Michels M; Soliman OI; Caliskan K; Galema TW; ten Cate FJ
J Cardiovasc Med (Hagerstown); 2009 Jan; 10(1):75-7. PubMed ID: 19145117
[TBL] [Abstract][Full Text] [Related]
11. A new Doppler signal enhancing agent for flow assessment in breast lesions.
Madjar H; Prömpeler HJ; Del Favero C; Hackelöer BJ; Llull JB
Eur J Ultrasound; 2000 Dec; 12(2):123-30. PubMed ID: 11118919
[TBL] [Abstract][Full Text] [Related]
12. Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.
Spinazzi A; Ceriati S; Pianezzola P; Lorusso V; Luzzani F; Fouillet X; Alvino S; Rummeny EJ
Invest Radiol; 2000 Jan; 35(1):1-7. PubMed ID: 10639031
[TBL] [Abstract][Full Text] [Related]
13. Safety Analysis of Adverse Events of Ultrasound Contrast Agent Lumason/SonoVue in 49,100 Patients.
Li Q; Yang K; Ji Y; Liu H; Fei X; Zhang Y; Li J; Luo Y
Ultrasound Med Biol; 2023 Feb; 49(2):454-459. PubMed ID: 36357252
[TBL] [Abstract][Full Text] [Related]
14. Adverse reactions after the use of SonoVue contrast agent: Characteristics and nursing care experience.
Hu C; Feng Y; Huang P; Jin J
Medicine (Baltimore); 2019 Nov; 98(44):e17745. PubMed ID: 31689827
[TBL] [Abstract][Full Text] [Related]
15. Anaphylactic shock with an ultrasound contrast agent.
Coudray S; Fabre C; Aichoun I; Perez-Martin A
J Med Vasc; 2017 Dec; 42(6):384-387. PubMed ID: 29203045
[TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
17. [Severe adverse reactions after the use of sulphur hexafluoride (SonoVue) as an ultrasonographic contrast agent].
de Groot MC; van Zwieten-Boot BJ; van Grootheest AC
Ned Tijdschr Geneeskd; 2004 Sep; 148(38):1887-8. PubMed ID: 15497786
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
19. Hepatic vein transit time of SonoVue: a comparative study with Levovist.
Lim AK; Patel N; Eckersley RJ; Goldin RD; Thomas HC; Cosgrove DO; Taylor-Robinson SD; Blomley MJ
Radiology; 2006 Jul; 240(1):130-5. PubMed ID: 16720867
[TBL] [Abstract][Full Text] [Related]
20. A Milestone: Approval of CEUS for Diagnostic Liver Imaging in Adults and Children in the USA.
Seitz K; Strobel D
Ultraschall Med; 2016 Jun; 37(3):229-32. PubMed ID: 27276056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
